Results 11 to 20 of about 54,207 (313)

Dasatinib-Related Chylothorax

Turkish Journal of Hematology, 2015
Dasatinib is a potent second-generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The most common adverse event associated with dasatinib therapy is fluid retention, including pleural effusion. Dasatinib-related chylothorax
Yen Min Huang, Cheng Hsu Wang, Jen Seng Huang, Kun Yun Yeh, Chien Hong Lai, Tsung Han Wu, Pei Hung Chang, Yueh Shih Chang, Yii Jenq Lan   +8 more
doaj   +4 more sources

Dasatinib/Prednisone Induction Followed by Blinatumomab/Dasatinib in Ph+ Acute Lymphoblastic Leukemia.

Blood Advances, 2022
Novel treatment strategies are needed for the treatment of Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) in older patients.
A. Advani, A. Moseley, K. O'Dwyer, B. Wood, Jae H. Park, M. Wieduwilt, D. Jeyakumar, George Yaghmour, E. Atallah, A. Gerds, S. O'brien, J. Liesveld, M. Othus, M. Litzow, R. Stone, E. Sharon, H. Erba   +16 more
semanticscholar   +5 more sources

A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities [PDF]

BLOOD RESEARCH, 2021
Chronic myeloid leukemia (CML), a myeloproliferative disorder caused by the over activity of BCR-ABL1 (breakpoint cluster region-Abelson), has been successfully treated by Tyrosine kinase inhibitors (TKIs).
Z. Nekoukar, M. Moghimi, E. Salehifar
semanticscholar   +4 more sources

Dasatinib inhibits CXCR4 signaling in chronic lymphocytic leukaemia cells and impairs migration towards CXCL12 [PDF]

, 2012
Chemokines and their ligands play a critical role in enabling chronic lymphocytic leukaemia (CLL) cells access to protective microenvironmental niches within tissues, ultimately resulting in chemoresistance and relapse: disruption of these signaling ...
A Hochhaus, A Ptasznik, A Serrels, A Veldurthy, AC Shor, Alison M. McCaig, Alison M. Michie, AM McCaig, CD Allen, CM Pleiman, DY Hallaert, Emilio Cosimo, J Hoellenriegel, J Hoellenriegel, JA Burger, JA Burger, JA Burger, JW Friedberg, LJ Lombardo, M Buchner, M Burger, M Lopez-Guerra, M Niedermeier, M O'Hayre, MF de Rooij, Michael T. Leach, MP Quiroga, O Hantschel, P Ghia, PC Amrein, R Buettner, RE Hayden, S Braselmann, S Ponader, S Willimott, SJ Richardson, Spencer B. Gibson, Y Nakata, Z Song   +38 more
core   +15 more sources

Dasatinib in accelerated phase [PDF]

Blood, 2007
[Comment on Guilhot et al, page 4143][1]The paper by Guilhot and colleagues extends the reported clinical experience with dasatinib in describing the outcome of 107 chronic myeloid leukemia (CML) patients treated with the drug in accelerated phase having failed, or been intolerant of, imatinib.
Stephen J. O’Brien
openalex   +3 more sources

Dasatinib—A Generation Ahead [PDF]

Indian Journal of Medical and Paediatric Oncology, 2021
AbstractDasatinib is a highly potent second-generation (2G) tyrosine kinase inhibitor (TKI) used in the management of Philadelphia (Ph) chromosome-positive leukemias, chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). In CML, dasatinib produces higher rates of early and deeper molecular responses compared with imatinib. The drug has
Subramaniam Murali Carthikeyan, Jayachandran Pk   +1 more
openaire   +2 more sources

Pharmacokinetics of Dasatinib [PDF]

Prague Medical Report, 2019
Tyrosine kinase inhibitors have recently become an essential tool in management of chronic myeloid leukaemia (CML). Dasatinib, a representative of those drugs, acts by inhibiting key proteins included in CML development, predominantly Bcr-Abl and Src. Its advantage is that it shows activity in many cases where other agents bring no improvement due to ...
Jana Hořínková, Ondřej Slanař, Martin Šíma   +2 more
openaire   +4 more sources

A Dasatinib-Induced Chylothorax Persisting After the Discontinuation of Dasatinib

European Journal of Case Reports in Internal Medicine, 2022
Dasatanib is a second-generation tyrosine kinase inhibitor with activity on the BCR-ABL fusion gene. it is used in the treatment of BCR-ABL positive chronic myeloid leukaemia and has the known side effect of pleural effusion. This usually involves exudate with the presence of lymphocytes. A more common side effect is the development of chylothorax.
Alexander Salembier, Patrick Alexander, Frederic Olbrechts, Nicolas Bradt   +3 more
openaire   +3 more sources

Treatment‐free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5‐year analysis of DASFREE

British Journal of Haematology, 2023
Patients with chronic myeloid leukaemia in chronic phase (CML‐CP) who have a sustained deep molecular response (DMR) are eligible to discontinue treatment and attempt treatment‐free remission (TFR). In the DASFREE study (ClinicalTrials.gov; NCT01850004),
N. Shah, V. García‐Gutiérrez, A. Jiménez-Velasco, Sarah M Larson, S. Saussele, D. Réa, F. Mahon, M. Levy, M. Gómez-Casares, M. Mauro, O. Sy, P. Martín-Regueira, J. Lipton   +12 more
semanticscholar   +1 more source

Dasatinib anhydrate containing oral formulation improves variability and bioavailability in humans

Leukemia, 2023
Dasatinib monohydrate indicated for the treatment of chronic myeloid leukemia displays pH-dependent solubility. The aim of reported development program of novel dasatinib anhydrate containing formulation was to demonstrate improved absorption and lower ...
Jiří Hofmann, Aleš Bartůněk, Tomáš Hauser, Gregor Sedmak, Josef Beránek, P. Ryšánek, M. Šíma, O. Slanař   +7 more
semanticscholar   +1 more source